An ad-free and cookie-free webpage by FactorPad
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Acadia Pharmaceuticals Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how ACAD stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Biotechnology industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
This is a new resource, spread the word, tell a friend